|
|
|
01 Sep 2010 |
ReVision's Fenretinide (RT-101) Reduced Incidence of Choroidal Neovascularization by More Than 50 Percent in Patients With Geographic Atrophy in a Phase 2b Trial
|
5 |
|
01 Sep 2010 |
Allergan, Inc. Receives FDA Approval for LUMIGAN(R) 0.01% as First-Line Therapy Indicated for the Reduction of Elevated Intraocular Pressure in Glaucoma Patients
|
4 |
|
01 Sep 2010 |
Otoprotective effect of AM-111 also shown in model of cochlear ischemia
|
4 |
|
01 Sep 2010 |
Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial
|
4 |
|
01 Sep 2010 |
Agensys, an Affiliate of Astellas, Announces Initiation of Phase I Clinical Trial of AGS-16M8F for Renal Cancer
|
5 |
|
31 Aug 2010 |
Halozyme Provides HYLENEX(R) Product Reintroduction Update
|
3 |
|
31 Aug 2010 |
Bionovo Receives Positive Guidance from FDA on Menerba
|
3 |
|
31 Aug 2010 |
Ovatech reports successful completion of Phase 2 clinical trial of Ovaprene non-hormonal intravaginal contraceptive ring
|
3 |
|
30 Aug 2010 |
Medicis Announces Approval of Additional Strengths of Solodyn(R)
|
4 |
|
27 Aug 2010 |
Exactech Acquires Minimally Invasive Spine Reconstruction Portfolio
|
5 |
|
27 Aug 2010 |
Basilea announces distribution agreement with Actelion for Toctino(R) in Canada
|
6 |
|
26 Aug 2010 |
FibroGen Announces Results of 2-Year Study Demonstrating that Biosynthetic Corneas Formulated with Recombinant Human Type III Collagen Restore Vision and Promote Nerve Regeneration
|
6 |
|
25 Aug 2010 |
Afferent Pharmaceuticals Announces Data Supporting Potential Utility of Proprietary P2X3 Antagonists in Regulating Bladder Reflexes
|
6 |
|
25 Aug 2010 |
Tranzyme Pharma to Present Ulimorelin Data Showing Reduction in Daily Vomiting in Patients with Diabetic Gastroparesis
|
3 |
|
25 Aug 2010 |
Inspire Pharmaceuticals, Inc. (ISPH) Stops Prolacria Development Program, Amends Agreement with Allergan Inc.
|
4 |
|
24 Aug 2010 |
Kamada and Baxter Enter into a Strategic Agreement for the Distribution and Manufacture of Intravenous Liquid AAT to Treat Alpha-1 Antitrypsin Deficiency in the US
|
4 |
|
23 Aug 2010 |
Novo Nordisk Inc. Announces Exclusive Agreement With Upsher-Smith Laboratories, Inc. to Market Vagifem 10 mcg
|
4 |
|
23 Aug 2010 |
InSite Vision Commences Phase 1/2 Clinical Study of ISV-303 for Post-Surgical Ocular Pain and Swelling
|
4 |
|
20 Aug 2010 |
Anchor Therapeutics Secures $10 Million Series B Financing to Advance Pepducin Drug Candidates
|
38 |
|
19 Aug 2010 |
International Stem Cell Corporation Formalizes Stem Cell-Based Eye Care Programs into Cytovis
|
4 |
|
19 Aug 2010 |
Perrigo Confirms Filing for Clobetasol Shampoo and Announcement of Patent Infringement Lawsuit by Galderma
|
4 |
|
18 Aug 2010 |
Palatin Technologies (PTN) Announces Positive Safety Results in Subcutaneous Bremelanotide Trial in Men
|
4 |
|
18 Aug 2010 |
Bolder BioTechnology Announces $600,000 Grant from NIH to Study Long-Acting IL-11 Analog in Treating Acute Radiation Syndrome
|
21 |
|
16 Aug 2010 |
FDA Grants Approval of ella(R) for Emergency Contraception
|
4 |
|
13 Aug 2010 |
LifeCycle Pharma Receives Special Protocol Assessment (SPA) From FDA for LCP-Tacro(TM) Pivotal Phase 3 Study in De Novo Kidney Transplant Patients
|
5 |
|
12 Aug 2010 |
Simcere Pharmaceutical Group Announces SFDA Approval to Manufacture and Market Palonosetron in China
|
5 |
|
11 Aug 2010 |
NeoStem and the Schepens Eye Research Institute to Study NeoStem's VSEL Technology in Retinal Diseases
|
6 |
|
11 Aug 2010 |
Urigen Pharmaceuticals Announces FDA Follow Up
|
7 |
|
11 Aug 2010 |
Agile Therapeutics Commences Phase 3 NEW CHOICE Study of AG200-15, Agile's Novel, Low-Dose Weekly Contraceptive Patch
|
7 |
|
11 Aug 2010 |
Depomed Reaches SPA Agreement With FDA for Phase 3 Hot Flash Trial
|
4 |
| |
|
Results 1 - 30 of 1699 |
